Daiichi Sankyo and AstraZeneca's Enhertu are continuing their unstoppable moves. Enhertu, which has achieved remarkable results in breast cancer, has expanded the types of carcinoma to include gastric cancer and lung cancer and is expected to be used in a number of solid cancers that show HER2 expression, such as cervical cancer, endometrial cancer, and ovarian cancer. Several ADCs have been approved, but none have been as scalable as Enhertu. Indeed, Enhertu is writing ADC history.

The phase 2 results for Enhertu announced at ASCO 2023 in June were very positive. Although it was not at a stage that deserved a standing ovation like last year's announcement of low-expression breast cancer of HER2, this